(PHILADELPHIA) — As the world’s leading professional organization representing physicians who treat people with cancer, the American Society of Clinical Oncology (ASCO) and many of its 25,000+ members  meet this weekend in Chicago at of the largest annual medical conferences in the world. Physicians from the Abramson Cancer Center of the University of Pennsylvania – like the rest of their ASCO colleagues – are committed to advancing the education of oncologists and other oncology professionals, to advocating for policies that provide access to high-quality cancer care, and to supporting the clinical trials system and the need for increased clinical and translational research.

Starting tomorrow, reporters can find in-depth, up-to-the-minute coverage of sessions and presentations from the annual ASCO meeting at OncoLink, the Abramson Cancer Center’s award-winning cancer resource website.

Friday, June 1st
1-4 p.m.

Integrating Imaging Tools for Cancer Screening and Patient Management
Should routine breast cancer staging include MRI?
Speaker/Education Book Manuscript Presentation:
Mitchell D. Schnall, MD, PhD

The Biology of Treagtment of HER2-Postitive Breast Cancer:  the Old and the New
“Where did it all begin?”
Speaker/Education Book Manuscript:
Mark I. Greene, MD

Saturday, June 2nd
7:30 – 10:30 a.m.

Melanoma – Oral Presentations
Lynn M Schuchter, MD
Discussion Leader:
Keith T. Flaherty, MD

8 a.m. – 12 p.m.

Lymphoma and Plasma Cell Disorders – General Poster Session
Poster No: U7             Abstract No. 8057
A two-arm prospective trial evaluating the ability of EBC iPCR to diagnose and monitor post-transplant lymphoproliferative disorder.
Donald E. Tsai, MD, PhD

Sunday, June 3rd
8 a.m. – 12 p.m.

Tumor Biology and Human Genetics
General Poster Session
Poster No: HH3           Abstract No. 10549
Pathologic predictors of BRCA1/BRCA2 (B!/B@) mutations in African-American women with early-onset breast cancer
Susan M. Domcheck, MD

9:15 – 10:30 a.m.

Time Management: Balancing Career and Family Life
Fellow Educators Session
Lynn M. Schuchter, MD

11 a.m. – 12:15 p.m.

When is a Molecular Test Ready for Routine Clinical Practice? - Presentation
How Should We Use Molecular Tests for Breast Cancer Treatment Decisions?
Angela DeMichele, MD

Sunday, June 3rd
1:15 -2:30 p.m.

Writing an Outstanding Scientific Manuscript – An Insider’s View from the Editor’s of the Journal of Clinical Oncology & Cell
Fellow Educators Session
Daniel G. Haller, MD

2 – 6 p.m.

Genitouirinary CAncer
General Poster Session
Poster No: F5              Abstract No. 5116
Prevalence of osteoporosis and osteopenia during androgen deprevation (ADT) for prostate cancer:  Baseline data from a large randomized controlled trial
S. Bruce Malkowicz, MD

Monday, June 4th
7:30 –8:45 a.m.

Evidence of Therapeutic Effectiveness:  How much is Enough to Change Clinical Practice?
Education Session
Introduction Speaker/Chair:
Susan Ellenberg, PhD

8 a.m. – 12 p.m.

Gastrointestinal (Colorectal) Cancer
General Poster Session
Poster No: E7              Abstract No. 4073
Magnitude of Progression-free survival improvement and treatment duration in metastatic colorectal cancer for bevacizumab in combination with oxaliplatin-containing regimens: An analysis of two phase III studies.
Bruce J. Giantonio, MD

9 a.m. – 12 p.m.

Breast Cancer – Local-Regional and Adjuvant Therapy
Oral Presentation
Discussion Leader:
Lawrence J. Solin, MD, FACR

11 a.m. – 12 p.m.

Head and Neck Cancer
Poster Discussion
Poster No: 3                Abstract No. 6019
Sorafenib targets BRAF and VEGER in metastatic thyroid carcinoma
Vandana Gupta, MD

11 a.m. – 12:15 p.m.

What Oncologists Should Know about Hereditary Gastric, Kidney, and Thyroid Cancers
Education Session
Introduction Speaker/Chair:
Susan M Domchek, MD

Thyroid abnormalities and inherited cancer syndromes
Education Session
Kate Nathanson, MD

5 – 6 p.m.

Poster Discussion
Poster No: 5                Abstract No. 10021
Utility of PET scan in predicting chemotherapeutic response in soft tissue sarcoma patients
David M. Mintzer, MD


The Abramson Cancer Center (ACC) of the University of Pennsylvania is a national leader in cancer research, patient care, and education. The pre-eminent position of the Cancer Center is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute for 30 years, one of 39 such Centers in the United States. The ACC is dedicated to innovative and compassionate cancer care. The clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists and patient care coordinators, currently sees over 50,000 outpatient visits, 3400 inpatient admissions, and provides over 24,000 chemotherapy treatments, and more than 65,000 radiation treatments. Not only is the ACC dedicated to providing state-of-the-art cancer care, the latest forms of cancer prevention, diagnosis, and treatment are available to our patients through clinical themes that developed in the relentless pursuit to eliminate the pain and suffering from cancer. In addition, the ACC is home to the 300 research scientists who work relentlessly to determine the pathogenesis of cancer. Together, the faculty are committed to improving the prevention, diagnosis and treatment of cancer. 

Founded in 1994 by Abramson Cancer Center specialists with a mission to help cancer patients, families, health care professionals and the general public get accurate cancer-related information at no charge, OncoLink is one of the oldest, largest, and most trusted sources for cancer information on the Internet.

PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.

Share This Page: